{"organizations": [], "uuid": "361a1449673fe10747be64d025ca61dc50cb0ae2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dar-bioscience-begins-trial-for-co/brief-dar-bioscience-begins-trial-for-contraceptive-candidate-ovaprene-idUSFWN1SM105", "country": "US", "domain_rank": 408, "title": "BRIEF-Daré Bioscience Begins Trial For Contraceptive Candidate Ovaprene", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.621, "site_type": "news", "published": "2018-05-15T20:09:00.000+03:00", "replies_count": 0, "uuid": "361a1449673fe10747be64d025ca61dc50cb0ae2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dar-bioscience-begins-trial-for-co/brief-dar-bioscience-begins-trial-for-contraceptive-candidate-ovaprene-idUSFWN1SM105", "ord_in_thread": 0, "title": "BRIEF-Daré Bioscience Begins Trial For Contraceptive Candidate Ovaprene", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-daré bioscience begins trial for contraceptive candidate ovaprene", "sentiment": "negative"}, {"name": "dare bioscience inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. ANNOUNCES TRIAL INITIATION FOR OVAPRENE® NON-HORMONAL MONTHLY CONTRACEPTIVE CANDIDATE\n* DARE BIOSCIENCE INC - DATA FROM OVAPRENE STUDY IS EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T20:09:00.000+03:00", "crawled": "2018-05-16T19:13:33.008+03:00", "highlightTitle": ""}